Bulletin
Investor Alert

Market Pulse Archives

Sept. 23, 2020, 5:28 p.m. EDT

Quadrant Biosciences gets FDA approval for saliva-based COVID-19 test

new
Watchlist Relevance
LEARN MORE

Want to see how this story relates to your watchlist?

Just add items to create a watchlist now:

or Cancel Already have a watchlist? Log In

By Wallace Witkowski

Quadrant Biosciences said late Wednesday it received an emergency approval from the Food and Drug Administration for a saliva-based COVID-19 test. The privately held Syracuse, N.Y.-based company developed the test along with State University of New York’s Upstate Medical University. Called the “Clarifi COVID-19” test, the diagnostic collects saliva with a swab and uses reagents to detect nucleic acid from SARS-CoV-2, the virus that causes COVID-19. The test is available for bulk purchases immediately by clinical laboratories for use at healthcare facilities, Quadrant said.

This Story has 0 Comments
Be the first to comment
More News In
Industries

Story Conversation

Commenting FAQs »
Link to MarketWatch's Slice.